Orna’s Approach & Strategy Paint Underline

We’re reshaping RNA therapeutics—shifting from linear to circular—to open an entirely new world of possibilities in the treatment of disease. Our engineered circular RNA (oRNA™) has unmatched advantages compared to linear forms, giving us confidence in the promise of changing patient lives.

speckled
Circular photo of an Orna scientist in a lab as she pipettes into a tube, encircled by an ombre red-yellow paint stroke

Limitless Potential Paint Underline

Orna’s technology has a breadth of applications across multiple disease areas including cancer, regenerative medicine, protein replacement, infectious diseases, and autoimmunity. Our lead program is an in situ CAR therapy that combines oRNA™ molecules and proprietary lipid nanoparticles (LNPs) to deliver chimeric antigen receptors (CARs) directly to patient’s immune cells within the body (isCAR™ therapy).

This off-the-shelf therapy would represent a significant advancement over traditional cell engineering therapies.

purple bg

About Us Paint Underline

Creating a new class of therapeutics requires thinking outside the lines. Comprising a team of skilled scientists, molecular engineers, and industry veterans in addition to a world class Board, we are well-suited for the challenge of bringing the promise of our oRNATM therapeutics to patients.

Our Team Paint Underline

LEADERSHIP
  • Leadership
  • Board of Directors
  • Investors
pink-rounded-shape
Thomas Barnes, PhD
Chief Executive Officer
pink-rounded-shape
Hope D’Oyley-Gay, JD
Chief Legal Officer
pink-rounded-shape
Michael Dube
Head of Facilities & Operations
pink-rounded-shape
Allen Horhota, PhD
Senior Director, Head of Delivery
pink-rounded-shape
Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology
pink-rounded-shape
Thomas Barnes, PhD
CEO, Orna Therapeutics
pink-rounded-shape
Thomas Ebeling
Advisor, MPM BioImpact Capital
pink-rounded-shape
Ansbert Gadicke, MD
Chairman of the Board, Co-founder & Managing Director, MPM BioImpact Capital
Astellas White Logo
MPM Biolmpact logo
f2-ventures-logo-white
kite-gilead-white
purple bg

News & Events Paint Underline

Orna Therapeutics Unveils Progress of Circular RNA Platform and Improvements in Lead Program ORN-101 at PEGS and ASGCT

CAMBRIDGE, Mass., May 18, 2023 — Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, presented data on the progress of lead program ORN-101, a development-stage in situ…

PEGS: In situ CAR Therapy Using oRNA

May 18, 2023 Amy M. Becker et al.
Orna Therapeutics Unveils Progress of Circular RNA Platform and Improvements in Lead Program ORN-101 at PEGS and ASGCT

ORN-101, an optimized development-stage in situ CAR program, shows tumor eradication in a mouse model at doses far lower than previously reported results

Orna’s FoRCE screening platform has enabled the identification of oRNAs that drive high protein expression, creating broad value across all of Orna’s programs

CAMBRIDGE, Mass., May 18, 2023 Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, presented data on the progress of lead program ORN-101, a development-stage in situ CAR program, at the Protein Engineering Summit (PEGS) and at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles.

The presentations include a session and talk at PEGS, as well as a poster presentation at ASGCT, which may be viewed on the Orna website here.

“Using the Orna FoRCE platform, we’ve been able to develop ORN-101, a potent anti-cancer circular RNA therapy delivered via LNP,” said Robert Mabry, PhD, Chief Scientific Officer at Orna. “We have achieved 20-fold lower dosing in animal models compared to earlier versions of the product, allowing us the flexibility to administer multiple doses of our off-the-shelf immunotherapy – something that could allow us to treat more patients quickly and easily.”

Synthetic Circular RNA as a New Therapeutic Modality

Elevated and durable protein expression – two features where mRNA falls short – are maximized with circular RNA in part due to Orna’s discovery of novel internal ribosome entry site (IRES) elements necessary for translation. Compared to previously known IRES elements, Orna’s library of IRES elements can be used to drive higher protein expression in desired cell type targets. oRNA, because of its shape, is more resistant to quick degradation in the body, is easier to manufacture and formulate in the lab, and is immunoquiescent. These desirable features further allow oRNA therapeutics to be developed for applications beyond infectious disease, including oncology and genetic disorders.

In situ CAR Therapy Using oRNA

Over the past four years, Orna has worked to develop a therapeutic class capable of delivering a chimeric antigen receptor (CAR) to immune cells within a patient, eliminating the need for lymphodepletion typically required for engineered cell therapies, while providing off-the-shelf redosability in an autologous setting. ORN-101 combines oRNA and a proprietary LNP, and these latest data show ORN-101’s tumor eradication ability after 2-3 doses in a mouse model, effective at 10-20-fold lower doses than Orna has previously reported. ORN-101 features high expression of the CAR driven by an optimized IRES element, selected by Orna’s FoRCE platform to yield durable protein expression.

About ORN-101:

ORN-101, Orna’s lead program, is a development-stage in situ CAR therapy designed to modify a patient’s immune cells inside their body. Comprising an oRNA molecule packaged inside a proprietary lipid nanoparticle (LNP) formulation, this easily redosable format could avoid patient lymphodepletion and allow for reliable dose control, overcoming barriers of existing autologous ex vivo CAR-T therapies without sacrificing efficacy. Preclinical data demonstrates tumor suppression and eradication in animal models, suggesting the possibility that oRNA-LNP based cancer therapies could disrupt traditional CAR-T cellular therapies.

About Orna Therapeutics:

Orna Therapeutics is reshaping RNA therapeutics to open a new world of treatment possibilities. Orna’s circular RNA (oRNA) is created in one step by self-circularization of an engineered linear RNA. In this form, oRNA enjoys unmatched advantages over traditional linear mRNA therapies including simplified production, increased protein expression, easier encapsulation into lipid nanoparticles (LNPs), and immunoquiescence. Orna’s proprietary LNPs deliver the oRNA to specific areas of the body, such as immune cells. Founded in 2019 based on groundbreaking research from MIT, Orna was built by MPM Capital and its affiliate BioImpact Capital. To learn more visit: www.ornatx.com and follow us on Twitter and LinkedIn.

Media Contact

Peg Rusconi, Verge Scientific Communications

prusconi@vergescientific.com

ASGCT: in Situ CAR Therapy Using oRNA Lipid Nanoparticles Regress Tumors In Vivo

May 18, 2023 Akinola Emmanuel et al.

PEGS: In situ CAR Therapy Using oRNA

May 18, 2023 Amy M. Becker et al.